BioCentury | Jul 24, 2017
Preclinical News

Group identifies ZFN326 gene as possible TNBC target

In a paper published in Cancer Research , researchers identified four tumor suppressor genes in triple-negative breast cancer, including one whose expression may be associated with patient survival. The paper's authors included researchers from Houston Methodist...
BioCentury | Jun 30, 2017
Clinical News

Boston Biomedical reports updated data from Phase Ib/II trial of amcasertib in solid tumors

...Amcasertib is a small molecule multi-kinase inhibitor of nanog homeobox (NANOG) and other cancer stem cell pathways...
...target: Nanog homeobox (NANOG) Description: Small molecule multi-kinase inhibitor of NANOG and other cancer stem cell pathways...
BioCentury | Jun 30, 2017
Clinical News

Boston Biomedical reports Phase Ib/II data for Nexavar combos in HCC

...BB503), a small molecule multi-kinase inhibitor of nanog homeobox (NANOG) and other cancer stem cell pathways...
BioCentury | Jun 13, 2016
Clinical News

Amcasertib: Updated Phase I data

...homeobox (NANOG) Description: Small molecule multi-kinase inhibitor of nanog homeobox (NANOG) and other cancer stem cell pathways...
BioCentury | May 30, 2016
Clinical News

Amcasertib: Additional Phase I data

...homeobox (NANOG) Description: Small molecule multi-kinase inhibitor of nanog homeobox (NANOG) and other cancer stem cell pathways...
BioCentury | Aug 13, 2015
Translation in Brief

Pain's he said/she said

Neurology Most preclinical studies are performed in male animals, but a new study suggests entirely different targets, pathways and cell types could be responsible for mechanical pain in males and females, and provides clues about...
BioCentury | Oct 20, 2014
Finance

Raising for Raze

Atlas Venture built platform company Raze Therapeutics Inc. to explore multiple targets and pathways associated with mitochondrial one-carbon metabolism, which the company thinks will supply novel targets to treat more cancers with fewer side effects...
BioCentury | Dec 9, 2013
Company News

Celgene, OncoMed deal

OncoMed granted Celgene exclusive options to jointly develop and commercialize up to six of OncoMed's cancer stem cell products, including demcizumab ( OMP-21M18 ). OncoMed will receive $155 million in cash up front. Celgene also will...
BioCentury | Dec 4, 2013
Top Story

Oncomed, Celgene in cancer deal

Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) jumped $13.70 (98%) to $27.70 on Tuesday after granting Celgene Corp. (NASDAQ:CELG) exclusive options to jointly develop and commercialize up to six of Oncomed's cancer stem cell products, including demcizumab ( OMP-21M18...
BioCentury | Mar 8, 2010
Strategy

OSI Chronicles

...including failures associated with its acquisitions of Cell Pathways Inc. and Eyetech Pharmaceuticals Inc .Aptosyn exisulind from Cell Pathways...
...externally funded entity focused on metabolic diseasesH. 2/10/03 - Says it will acquire cancer company Cell Pathways...
Items per page:
1 - 10 of 187
BioCentury | Jul 24, 2017
Preclinical News

Group identifies ZFN326 gene as possible TNBC target

In a paper published in Cancer Research , researchers identified four tumor suppressor genes in triple-negative breast cancer, including one whose expression may be associated with patient survival. The paper's authors included researchers from Houston Methodist...
BioCentury | Jun 30, 2017
Clinical News

Boston Biomedical reports updated data from Phase Ib/II trial of amcasertib in solid tumors

...Amcasertib is a small molecule multi-kinase inhibitor of nanog homeobox (NANOG) and other cancer stem cell pathways...
...target: Nanog homeobox (NANOG) Description: Small molecule multi-kinase inhibitor of NANOG and other cancer stem cell pathways...
BioCentury | Jun 30, 2017
Clinical News

Boston Biomedical reports Phase Ib/II data for Nexavar combos in HCC

...BB503), a small molecule multi-kinase inhibitor of nanog homeobox (NANOG) and other cancer stem cell pathways...
BioCentury | Jun 13, 2016
Clinical News

Amcasertib: Updated Phase I data

...homeobox (NANOG) Description: Small molecule multi-kinase inhibitor of nanog homeobox (NANOG) and other cancer stem cell pathways...
BioCentury | May 30, 2016
Clinical News

Amcasertib: Additional Phase I data

...homeobox (NANOG) Description: Small molecule multi-kinase inhibitor of nanog homeobox (NANOG) and other cancer stem cell pathways...
BioCentury | Aug 13, 2015
Translation in Brief

Pain's he said/she said

Neurology Most preclinical studies are performed in male animals, but a new study suggests entirely different targets, pathways and cell types could be responsible for mechanical pain in males and females, and provides clues about...
BioCentury | Oct 20, 2014
Finance

Raising for Raze

Atlas Venture built platform company Raze Therapeutics Inc. to explore multiple targets and pathways associated with mitochondrial one-carbon metabolism, which the company thinks will supply novel targets to treat more cancers with fewer side effects...
BioCentury | Dec 9, 2013
Company News

Celgene, OncoMed deal

OncoMed granted Celgene exclusive options to jointly develop and commercialize up to six of OncoMed's cancer stem cell products, including demcizumab ( OMP-21M18 ). OncoMed will receive $155 million in cash up front. Celgene also will...
BioCentury | Dec 4, 2013
Top Story

Oncomed, Celgene in cancer deal

Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) jumped $13.70 (98%) to $27.70 on Tuesday after granting Celgene Corp. (NASDAQ:CELG) exclusive options to jointly develop and commercialize up to six of Oncomed's cancer stem cell products, including demcizumab ( OMP-21M18...
BioCentury | Mar 8, 2010
Strategy

OSI Chronicles

...including failures associated with its acquisitions of Cell Pathways Inc. and Eyetech Pharmaceuticals Inc .Aptosyn exisulind from Cell Pathways...
...externally funded entity focused on metabolic diseasesH. 2/10/03 - Says it will acquire cancer company Cell Pathways...
Items per page:
1 - 10 of 187